AbbVie Inc (ABBV) FY2025 10-K Annual Report
AbbVie Inc (ABBV) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 20, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
AbbVie Inc FY2025 10-K Analysis
Business Overview
- • Core business: global biopharmaceutical company focused on innovative therapies in immunology, neuroscience, oncology, aesthetics, and eye care
- • New emphasis: expanded indications and geographic approvals for Skyrizi and Rinvoq across autoimmune diseases, plus new oncology ADC Epkinly approved for lymphoma
- • Strategic shift: single global business segment operating model aligned for unified resource allocation and long-term strategic goal achievement
- • Quantitative highlight: 2025 gross revenues in U.S. distributed mostly through three wholesalers, none exceeding 43% share
- • Noteworthy fact: continued biosimilar competition pressure on Humira globally, with evolving FDA regulatory pathway and complex approval process
Management Discussion & Analysis
- • Revenue $61.2B, up 9% YoY on reported and constant currency basis
- • Operating earnings $15.1B, operating margin approximately 24.7% (15.1B/61.2B)
- • Best segment: not explicitly broken down; costs include $7.4B amortization, $6.5B contingent liabilities fair value change
- • Cash flow from operations $19.0B, no disclosed buybacks or dividends, ongoing investment in pipeline and brands
- • Forward outlook: $100B pledged for US R&D/capex over decade, tariff exemption for 3 years, risk of revenue erosion from Medicare price controls starting 2026
Risk Factors
- • FDA approval and EC marketing authorization for Rinvoq in 2025 for giant cell arteritis and ulcerative colitis, supporting U.S. exclusivity through April 2037
- • Global minimum tax "Pillar Two" implementation starting 2024 raising future income tax expense uncertainty under OECD rules
- • Capital investment including new U.S. API facility in Illinois and biologics expansion in Massachusetts increases operational complexity and execution risk
- • Biosimilar competition driving Humira U.S. net revenues down 57% in 2025 threatens market position and revenue stability
- • $6.5B contingent consideration liabilities fair value increase in 2025 linked to Skyrizi sales projections creating significant financial risk exposure
AbbVie Inc FY2025 Key Financial MetricsXBRL
Revenue
$61.2B
▲ +8.6% YoY
Net Income
$4.2B
▼ -1.2% YoY
Gross Margin
19.7%
▲ +72bp YoY
Operating Margin
24.6%
▲ +843bp YoY
Net Margin
6.9%
▼ -68bp YoY
ROE
-129.2%
▼ -25790bp YoY
Total Assets
$134.0B
▼ -0.9% YoY
EPS (Diluted)
$2.36
▼ -1.3% YoY
Operating Cash Flow
$19.0B
▲ +1.2% YoY
Source: XBRL data from AbbVie Inc FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on AbbVie Inc
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.